PARSIPPANY, NJ, Oct. 28, 2009 (Marketwire) --

PARSIPPANY, NJ -- (Marketwire) -- 10/28/09 -- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the third quarter of 2009.

Financial highlights for the third quarter of 2009:

--  Net revenue increased by 12% to $98.8 million for the third quarter of
    2009 from $88.1 million for the third quarter of 2008.

    --  Angiomax U.S. sales increased by 9% to $92.2 million in the third
        quarter of 2009 compared to $85.0 million in the third quarter of
        2008.

    --  Angiomax/Angiox international net revenue in the third quarter of
        2009 increased by 74% to $5.5 million compared to $3.1 million in
        the third quarter of 2008.

    --  Cleviprex has now been accepted by more than 345 hospital
        formularies and has been purchased by more than 400 hospitals in
        the United States. Net revenue in the third quarter of 2009 was
        $1.1 million, up from $0.9 million in the second quarter.

--  Net loss for the third quarter of 2009 was ($3.2) million, or ($0.06)
    per share, compared to a net loss of ($13.2) million, or ($0.25) per
    share, for the third quarter of 2008.

--  Non-GAAP net income for the third quarter of 2009 was $5.1 million, or
    $0.10 per share, compared to non-GAAP net income of $8.5 million, or
    $0.16 per share, for the third quarter of 2008.  Non-GAAP net income
    excludes the transaction costs associated with the Targanta and
    Curacyte acquisitions, stock-based compensation expense and non-cash
    income taxes.

Clive Meanwell, Chairman and Chief Executive Officer, stated, "This was a challenging quarter in terms of market dynamics. We estimate that inpatient PCI volume declined 9% year on year, including a dramatic 17 % reduction in elective PCIs, set against a 4% increase in emergent or urgent procedures. Despite this, we grew U.S. Angiomax volume and year on year, net sales worldwide are up 19%. Angiox and Cleviprex are beginning to make meaningful contributions to our top line. Our development programs are making progress."

Recent operational highlights:

--  HORIZONS-AMI one-year trial results were published in The Lancet. The
    trial showed that Angiomax reduced cardiac-related death by 43 percent (p
    equals 0.005), improved overall survival by 27 percent (p equals 0.037) and
    reduced major bleeding complications by 39 percent (p is less than 0.0001)
    compared with heparin plus a GP IIb/IIIa inhibitor. Angiomax showed an
    absolute reduction of 1.7 percent in cardiac-related death and 1.3 percent
    in all-cause death at one year.

--  The United States Patent and Trademark Office issued 2 new patents
    relating to a more consistent and improved Angiomax drug product, which
    were listed in the U.S. Food and Drug Administration's publication
    "Approved Drug Products with Therapeutic Equivalence Evaluations," which is
    commonly known as the Orange Book, for Angiomax.

--  The Company entered into a license agreement with Eagle
    Pharmaceuticals, Inc. under which The Medicines Company will have rights in
    the United States and Canada to an innovative, ready-to-use formulation of
    Argatroban, which is currently under review by the U.S. Food and Drug
    Administration (FDA).

--  The Committee for Medicinal Products for Human Use (CHMP) granted a
    positive opinion applicable to all Member States of the European
    Union/European Economic Area that will extend the use of Angiox to include
    patients with heart attacks (so-called ST segment elevation myocardial
    infarction (STEMI)) undergoing emergency heart procedures called primary
    percutaneous coronary intervention (PCI).
    

Financial highlights for the first nine months of 2009:

--  Net revenue increased by 19% to $302.2 million for the first nine
    months of 2009 from $254.3 million for the same period in 2008.

    --  Angiomax U.S. sales increased by 16% to $286.6 million for the
        first nine months of 2009 from $246.3 million for the first nine
        months of 2008.

    --  Angiomax/Angiox international net revenue in the first nine months
        of 2009 increased by 64% to $13.1 million compared to $8.0 million
        in the first nine months of 2008.

    --  Cleviprex net revenue in the first nine months of 2009 was
        $2.5 million.

--  Net loss for the first nine months of 2009 was ($2.7) million, or
    ($0.05) per share, and includes costs for the Targanta acquisition,
    compared to net loss of ($4.3) million, or ($0.08) per share, in the
    first nine months of 2008.

--  The Company reported non-GAAP net income of $20.9 million, or $0.40 per
    share, for the first nine months of 2009, compared to non-GAAP net
    income of $35.4 million, or $0.68 per share, for the first nine months
    of 2008. Non-GAAP net income excludes the Targanta and Curacyte
    acquisitions, stock-based compensation expense and non-cash income
    taxes.

The following table provides reconciliations between GAAP and non-GAAP net (loss) income for the third quarter (Q3) and first nine months (9M) of 2009 and 2008. Non-GAAP net income excludes the transaction charges related to the Targanta and Curacyte acquisitions, stock-based compensation expense and non-cash income taxes:

                                              FAS 123R   Non-Cash
                                                Stock-  (Benefit)
               Reported   Targanta  Curacyte    Based   Provision
               GAAP Net    Trans-    Acquisi-  Compen-     for    Non-GAAP
                (Loss)     action     tion     sation    Income      Net
(in millions)   Income      Costs     Costs    Expense    Taxes   Income(1)
                --------  --------- --------- --------- --------- ---------
Q3 2009         ($   3.2)         -         - $     4.4 $     3.8 $     5.1
                --------  --------- --------- --------- --------- ---------
Q3 2008         ($  13.2)         - $    13.2 $     6.0 $     2.5 $     8.5
                --------  --------- --------- --------- --------- ---------
9M 2009         ($   2.7) $     4.3         - $    15.3 $     4.0 $    20.9
                --------  --------- --------- --------- --------- ---------
9M 2008         ($   4.3)         - $    13.2 $    17.4 $     9.1 $    35.4
                --------  --------- --------- --------- --------- ---------

Note: Amounts may not sum due to rounding.

(1) Excluding the transaction charges related to the Targanta and Curacyte acquisitions, stock-based compensation expense and non-cash income taxes.

Reconciliations between GAAP and non-GAAP fully diluted (loss) earnings per share (EPS) for the third quarter (Q3) and first nine months (9M) of 2009 and 2008 are provided in the following table:

                                              FAS 123R   Non-Cash
                Reported                        Stock-  (Benefit)
                  GAAP    Targanta  Curacyte    Based   Provision
                 (Loss)    Trans-    Acquisi-  Compen-     for
                Earnings   action     tion     sation    Income   Non-GAAP
(in millions)  Per Share    Costs     Costs    Expense    Taxes     EPS(1)
                --------  --------- --------- --------- --------- ---------
Q3 2009         ($  0.06)         -         - $    0.09 $    0.07 $    0.10
                --------  --------- --------- --------- --------- ---------
Q3 2008         ($  0.25)         - $    0.25 $    0.11 $    0.05 $    0.16
                --------  --------- --------- --------- --------- ---------
9M 2009         ($  0.05) $    0.08         - $    0.29 $    0.08 $    0.40
                --------  --------- --------- --------- --------- ---------
9M 2008         ($  0.08)         - $    0.25 $    0.34 $    0.18 $    0.68
                --------  --------- --------- --------- --------- ---------

Note: Amounts may not sum due to rounding.

(1) Excluding the transaction charges related to the Targanta and Curacyte acquisitions, stock-based compensation expense and non-cash income taxes.

The Company believes that presenting the non-GAAP information contained in the financial tables and in this press release assists investors and others in gaining a better understanding of the Company's core operating results and future prospects, expected growth rates or forecasted guidance, particularly as related to transaction charges associated with the Targanta acquisition, stock-based compensation expense and non-cash income taxes. Management uses this non-GAAP information, in addition to the GAAP information, as the basis for measuring the Company's core operating performance and comparing such performance to that of prior periods and to the performance of its competitors. Such measures are also used by management in its financial and operating decision-making. Non-GAAP information is not meant to be considered superior to or a substitute for the Company's results of operations prepared in accordance with GAAP.